MedTrace Logo

The Efficacy and Neurobehavioural Mechanism of N-acetyl Cysteine (NAC) for Alcohol Dependence

NCT03879759 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-03-19

No results posted yet for this study

Summary

The study will explore the efficacy and tolerability of a regimen of NAC (2400 mg) versus placebo for the treatment of alcohol dependence.

Conditions

  • Alcohol Dependence

Interventions

DRUG

NAC 2400mg/day

2400mg/day 2 x 600mg b.d

DRUG

Placebo

4 matched placebo tablets/day

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • University of Sydney

    collaborator OTHER

  • South West Sydney Local Health District

    lead OTHER

Principal Investigators

  • Paul S Haber, MBBS · Sydney Local Health District

  • Andrew Baille, PhD · Macquarie University

  • Kirsten Morley, PhD · University of Sydney

  • Warren B Logge, PhD · Sydney Local Health District

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-22
Primary Completion
2020-11-30
Completion
2020-11-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03879759 on ClinicalTrials.gov